

REDX PHARMA PLC
("Redx" or "the Company")

Redx to Present Preclinical Data Poster for RXC007 at the European Respiratory Society International Congress

Alderley Park, 31 August 2022 Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that it will present a poster on RXC007 at the forthcoming European Respiratory Society (ERS) International Congress (4-6 September 2022, Barcelona, Spain/virtual).

The poster will present preclinical data on the potential benefits of RXC007, Redx's lead fibrosis asset, based on *ex vivo* and *in vivo* models of pulmonary fibrosis. RXC007 is an orally available, highly selective small molecule inhibitor that targets Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) which sits at a nodal point in cell signalling pathways associated with fibrosis. RXC007 is expected to enter Phase 2a clinical studies in idiopathic pulmonary fibrosis (IPF) in 2022, following encouraging Phase 1 safety and pharmacokinetic data.

Title: Effects of RXC007, a highly potent and selective ROCK2 inhibitor, in *ex vivo* and *in vivo* models of pulmonary fibrosis

Abstract: PA453

Day/Date: Sunday, 4 September 2022

Session name and category: TP-24 - Interstitial lung diseases diagnosis in the COVID-19 era: new tools for new challenges

A copy of the poster will be made available on the Company's website following the presentation at: <https://www.redxpharma.com/scientific-publications/>

For further information, please contact:

Redx Pharma Plc

UK Headquarters

T: +44 (0)1625 469 918

Caitlin Pearson, Head of Communications ir@redxpharma.com

Lisa Anson, Chief Executive Officer

US Office

Peter Collum, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser)

Matt Davis/ Adam Dawes

T: +44 (0)203 368 3550

WG Partners LLP (Joint Broker)

Claes Spång/ Satheesh Nadarajah/ David Wilson

T: +44 (0)203 705 9330

Panmure Gordon (UK) Limited (Joint Broker)

Rupert Dearden/ Freddy Crossley/ Emma Earl

T: +44 (0)207 886 2500

FTI Consulting

Simon Conway/ Ciara Martin

T: +44 (0)203 727 1000

About Redx Pharma Plc

Redx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept before evaluating options for further development and potential value creation. Redx's lead oncology product candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor product candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. Encouraging safety and pharmacokinetic data has been reported, and a Phase 2 clinical program is confirmed to start in 2022. Redx's third drug candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment of fibrostenotic Crohn's disease, is currently in pre-IND stage, with Phase 1 clinical studies expected to commence in 2023.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. The Company's accomplishments are evidenced not only by its two wholly-owned clinical-stage product candidates and rapidly expanding pipeline, but also by its strategic transactions, including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in Phase 3 clinical development by Eli Lilly following its acquisition of Loxo Oncology and RXC006, a Porcupine inhibitor targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF), which AstraZeneca is progressing in a Phase 1 clinical study. In addition, Redx has forged collaborations with Jazz Pharmaceuticals, which includes JZP815, a preclinical pan-RAF inhibitor, which has received IND clearance from the US FDA, and an early stage oncology research collaboration.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFLFFLTDIIVIF